Evidence map›Paper›PMID 29594605›Full record

ReviewClinical autonomic research : official journal of the Clinical Autonomic Research Society2018

Autonomic nervous system and cancer.

Marta Simó, Xavier Navarro, Victor J Yuste, Jordi Bruna

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Sympathetic and parasympathetic innervation in cancer: therapeutic implications.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2021
    Review
  16. Article
  17. Targeting pheochromocytoma/paraganglioma with polyamine inhibitors.Metabolism: clinical and experimental · 2020
    Article
  18. Review
  19. Beyond the tumour microenvironment.International journal of cancer · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Marta SimóNeuro-Oncology Unit, Hospital Universitari de Bellvitge-Catalan Institute of Oncology (ICO) l'Hospitalet, Bellvitge Institute for Biomedical Research (IDIBELL), Feixa Llarga s/n, 08907, L'Hospitalet de Llobregat, Barcelona, Spain.
Xavier NavarroDepartment of Cell Biology, Physiology and Immunology, Institute of Neurosciences, Faculty of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain.
Victor J YusteCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Bellaterra, Barcelona, Spain.
Jordi BrunaNeuro-Oncology Unit, Hospital Universitari de Bellvitge-Catalan Institute of Oncology (ICO) l'Hospitalet, Bellvitge Institute for Biomedical Research (IDIBELL), Feixa Llarga s/n, 08907, L'Hospitalet de Llobregat, Barcelona, Spain. 35078jbe@comb.cat.ORCID 0000-0001-6895-5047
Universitat Autònoma de Barcelona · ESBellvitge University Hospital · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The autonomic nervous system (ANS) is the main homeostatic regulatory system of the body. However, this widely distributed neural network can be easily affected by cancer and by the adverse events induced by cancer treatments. In this review, we have classified the ANS complications of cancer into two categories. The first includes direct cancer-related complications, such as primary ANS tumors (pheochromocytoma, paraganglioma or neuroblastoma), as well as autonomic manifestations induced by non-primary ANS tumors (primary brain tumors and metastases). The second comprises indirect ANS complications, which include autonomic features related to cancer therapy (chemotherapy, radiotherapy and/or surgery) and those not related to cancer therapy, such as paraneoplastic autonomic syndromes. We also review the molecular relationship and modulation between the ANS and the cancer cells and their microenvironment.

Indexed as

Antineoplastic AgentsAutonomic Nervous SystemAutonomic Nervous System DiseasesHumansNeoplasmsPostoperative ComplicationsRadiotherapyAntineoplastic AgentsAutonomic nervous systemCancerNeoplasmParasympatheticSympathetic

Identifiers

PMID29594605
OpenAlexW2794442747

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.